The WiTT Group and Mary Crowley Cancer Research form partership to enhance access to clinical trials

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The WiTT Group Inc., a company focused on solving the non-clinical challenges patients face as they go through cancer treatment, formed a partnership Mary Crowley Cancer Research to identify and help patients gain access to clinical trials.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Primary results from the phase III POD1UM-303/InterAACT 2 trial of retifanlimab (Zynyz), a humanized monoclonal antibody targeting programmed death receptor-1, in combination with carboplatin and paclitaxel (platinum-based chemotherapy) in adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal cancer who have not been previously treated with systemic chemotherapy, were published in The Lancet. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login